HER2 Testing: The Evolving Role of Immunohistochemistry (IHC)
Fernando López-Ríos, MD, PhD
Christian Rolfo, MD, PhD
Charlie Gourley, MD, PhD
Defining the Standard of Care and Optimal Sequencing in BRAF-Mutant mCRC: Second Line and Beyond
Fortunato Ciardiello, MD, PhD
Jenny Seligmann, MBChB, PhD
From Guidelines to Practice: First-Line Treatment Choices in mCRC
Exploring New and Emerging Treatments in Muscle Invasive Bladder Cancer
Elizabeth R. Plimack, MD, MS, FASCO
Understanding the Expanding Role of Antibody-Drug Conjugates in Bladder Cancer
Lillibeth Velasco, MSN, RN
Patient Perspectives on Bladder Cancer
Advancing TROP-2-Targeted ADCs in HR+ Breast Cancer: Navigating Today and Shaping Tomorrow
Javier Cortes, MD, PhD
Hope S. Rugo, MD, FASCO
Molecular Profiling for HER2+ Advanced Solid Tumors
Eric Van Cutsem, MD, PhD
David SP Tan, MBBS, PhD, PRCP
James Chih-Hsin Yang, MD, PhD
Kathleen Moore, MD, MS, FASCO
Metastatic Pancreatic Ductal Adenocarcinoma (PDAC): From Diagnosis to Treatment
Efrat Dotan, MD
Shubham Pant, MD, MBBS
Biomarker-Directed Approaches for Frontline Treatment of Advanced Gastric/GEJ Cancers: The Evidence
Sara Lonardi, MD
The Role of Biomarker-Driven Therapies in the Second-Line Treatment of Advanced Gastric/GEJ Cancers: What Do the Data Say?
The Evolving Treatment Landscape for MBC: Emerging Therapies
William J. Gradishar, MD
Immunotherapy for TNBC in the Perioperative Setting: Clinical Evidence and Considerations
Peter Schmid, FRCP, MD, PhD
Guideline Recommendations for the Definition and Treatment of HER2-Low Breast Cancer
Erica L. Mayer, MD, MPH
Management of HER2-Low MBC Following First-Line Disease Progression
Applying Current Guidelines in the First-Line Treatment of MSI-H/dMMR mCRC—A Case Discussion
Aparna R. Parikh, MD
Loading...
NEW FEATURES:
Tell us what you think by using the Feedback button on the right side of the page.
We're glad to see you're enjoying Global Oncology Academy… but how about a more personalized experience?
Press cancel to remain on Global Oncology Academy. Press the link below or the continue button to keep going.